Leadership & Management
Roche Diagnostics MD decodes ‘grounded leader’ playbook amid escalating complexity

Navigating a health system under intensifying pressure and accelerating uncertainty, Anand Vairavan, Managing Director of Roche Diagnostics Australia joins this Health Industry Hub senior leadership podcast series to explore how complex clashes are redefining the very nature of leadership.
The discussion is framed by the University of Sydney leadership report authored by Professors Sandra Peter and Kai Riemer, whose work explores a ‘decade of disorientation’ and why the ‘grounded leader’ is best positioned to lead teams.
The growing corporate instinct to treat artificial intelligence (AI) as a shortcut to transformation is firmly challenged. Instead, Vairavan reflects on the reality of leading a workforce through technological change while maintaining the balance of “efficiency and expertise” inside an already complex environment.
Equally pressing is the issue of public trust.
As confidence in leaders continues to fracture globally, the conversation examines the growing perception that businesses are extracting rather than adding value, and how organisations like Roche are being challenged to reshape that narrative among key stakeholders, including patients, clinicians and government.
In sharing his advice with the next generation of senior leaders, Vairavan argues that leading in this ‘decade of disorientation’ increasingly comes down to the ability to “create clarity, build trust, and give people the space and support to do great work”.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - Pharmaceuticals
Inside the tensions shaping PBAC decision
The evolving relationship between sponsors, the Pharmaceutical Benefits Advisory Committee (PBAC) and the health technology assessment (HTA) system came under […]
MoreNews - MedTech & Diagnostics
GenesisCare and Omico join forces in precision oncology as Australia sets national genomics agenda
GenesisCare and Omico are teaming up to bring precision oncology to more patients facing incurable, advanced or poor prognosis cancers. […]
MoreNews - MedTech & Diagnostics
MTAA Board election kicks off, setting stage for the next chapter in policy and advocacy
The race for six seats on the Medical Technology Association of Australia (MTAA) Board is underway, with 10 candidates nominated […]
MoreNews - Pharmaceuticals
New breast cancer drug fills gap left by Zoladex market withdrawal
From 1 October 2026, Diphereline (triptorelin 3.75mg) will become available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of […]
More